



Anticancer Drugs Activity and Underlying Mechanism

Guest Editors:

Dr. Apostolos E. Papalois

2nd Department of Surgery,
School of Medicine, National and
Kapodistrian University of
Athens, Athens, Greece

**Dr. Georgios Antonios
Margonis**

Department of Surgery, Memorial
Sloan Kettering Cancer Center,
New York, NY 10065, USA

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

The National Cancer Institute defines oncologic precision medicine as the “use of specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.” Specific information about a person’s tumor includes the identification of specific molecules (“molecular targets”) that are involved in the growth, progression, and spread of cancer. Examples of conceptually different molecular targets include the overexpression of the normally expressed HER2+ protein and the expression of the abnormal (mutated) BRAF protein. These molecules are then targeted by drugs or other substances which collectively constitute the targeted cancer therapies. Since the advent of the first small molecule targeted agent (the BCR-ABL kinase inhibitor imatinib) three decades ago, the targeted, mechanism-based therapeutics along with immunotherapy have changed the paradigm for cancer treatment, which used to rely on relatively non-specific cytotoxic agents. This special issue invites original and review papers on targeted cancer therapies in any malignancy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI